Claims for Patent: 8,946,235

Summary for Patent: 8,946,235

Title:	2-(2,4,5-substituted-anilino) pyrimidine compounds
Abstract:	The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.
Inventor(s):	Butterworth; Sam (Cheshire, GB), Finlay; Maurice Raymond Verschoyle (Cheshire, GB), Ward; Richard Andrew (Cheshire, GB), Redfearn; Heather Marie (Cheshire, GB)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	13/557,871
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,946,235
Patent Claims:	1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide. 2. A pharmaceutical composition, which comprises the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier. 3. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof. 4. A compound, wherein the compound is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide. 5. A pharmaceutical composition, which comprises the compound according to claim 4, in association with a pharmaceutically-acceptable diluent or carrier. 6. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the compound of claim 4. 7. A mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-- yppyrimidin-2-yl]amino}phenyl)prop-2-enamide. 8. A pharmaceutical composition, which comprises the mesylate salt according to claim 7, in association with a pharmaceutically-acceptable diluent or carrier. 9. A method for treating lung cancer in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of the mesylate salt of claim 7. 10. The method of claim 3, wherein the lung cancer is non-small cell lung cancer. 11. The method of claim 6, wherein the lung cancer is non-small cell lung cancer. 12. The method of claim 9, wherein the lung cancer is non-small cell lung cancer.